Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease

Jangampalli Adi Pradeepkiran, Arubala P. Reddy, P. Hemachandra Reddy

Research output: Contribution to journalReview article

11 Scopus citations

Abstract

Phosphorylated tau (P-tau) has received much attention in the field of Alzheimer's disease (AD), as a potential therapeutic target owing to its involvement with synaptic damage and neuronal dysfunction. The continuous failure of amyloid β (Aβ)-targeted therapeutics highlights the urgency to consider alternative therapeutic strategies for AD. The present review describes the latest developments in tau biology and function. It also explains abnormal interactions between P-tau with Aβ and the mitochondrial fission protein Drp1, leading to excessive mitochondrial fragmentation and synaptic damage in AD neurons. This article also addresses 3D pharmacophore-based drug models designed to treat patients with AD and other tauopathies.

Original languageEnglish
Pages (from-to)616-623
Number of pages8
JournalDrug Discovery Today
Volume24
Issue number2
DOIs
StatePublished - Feb 2019

Fingerprint Dive into the research topics of 'Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease'. Together they form a unique fingerprint.

Cite this